Evidence map›Paper›PMID 40056327›Full record

ArticleMolecular diversity2025

An innovative approach to development of new pyrazolylquinolin-2-one hybrids as dual EGFR and BRAF

Mohamed M Hawwas, Ahmed S Mancy, Mohamed Ramadan, Tarek S Ibrahim, Ashraf H Bayoumi, Mohamed Alswah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed M HawwasDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Ahmed S MancyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Mohamed RamadanDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt. elbashamohammed@azhar.edu.eg.
Tarek S IbrahimDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Ashraf H BayoumiDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Mohamed AlswahDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel quinoline-based derivatives 2a-e and 4a-j have been designed and synthesized as potential antiproliferative agents. The designed compounds were screened for their antiproliferative activity against sixty cell lines according to NCI protocol. The promising hybrids 4d-g are screened by MTT assays on three cancer cell lines: leukemia (MOLT-4), lung cancer (HOP-92), and breast cancer (T47D), with IC

Indexed as

Antineoplastic AgentsErbB ReceptorsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrazolesQuinolonesApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsBRAF protein, humanEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrazolesQuinolonesAntiproliferativeBRAFV600EEGFRPyrazoleQuinoline

Identifiers

PMID40056327
PMCPMC12638379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.